4.3 Article

Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit

Journal

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
Volume 91, Issue 3, Pages 224-234

Publisher

WILEY
DOI: 10.1111/j.1365-2613.2009.00700.x

Keywords

angioplasty; atherosclerosis; EGFR; macrophages; neointima formation

Categories

Funding

  1. British Heart Foundation

Ask authors/readers for more resources

P>Monocyte recruitment and their differentiation into macrophages are both early events in native and accelerated atherosclerosis that follows angioplasty. We have investigated the putative functional role of the epidermal growth factor receptor (EGFR) present on rabbit monocytes/macrophages. The impact of periadventitial delivery of an EGFR-specific, blocking monoclonal antibody (ICR62, which inhibits EGF-binding to its receptor) was investigated in a rabbit model of accelerated atherosclerosis induced by a combination of carotid injury and 4 weeks of a 2% cholesterol-diet. Two weeks after the initiation of the diet, a balloon-catheter angioplasty of the left common carotid artery was performed and a collar placed around the injured carotid artery immediately, for the delivery of ICR62 antibody, isotype-matched antibody or saline control. Monocyte/macrophage accumulation, cell proliferation and neointimal thickening were determined 2 weeks after the delivery of the antibodies. The function of the EGFR on rabbit monocytes was also investigated in vitro, using chemotaxis assays. Treatment with ICR62 was associated with a significant reduction in macrophage accumulation and neointimal thickening and a 76% reduction in neointimal area of the vessel wall compared with controls. In vitro ICR62 inhibited macrophage and smooth muscle cell migration towards EGFR ligands including EGF and HB-EGF. These findings suggest that EGFR ligation may be important in the development of early atherosclerotic lesions following balloon-catheter angioplasty, and periadventitial delivery may provide a feasible approach for administration of the inhibitors of EGFR-binding such as ICR62.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

Said A. Khelwatty, Sharadah Essapen, Alan M. Seddon, Zhen Fan, Helmout Modjtahedi

BRITISH JOURNAL OF CANCER (2015)

Article Immunology

Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model

Samer Bazzi, Helmout Modjtahedi, Satvinder Mudan, Charles Akle, Georges M. Bahr

IMMUNOBIOLOGY (2015)

Article Oncology

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition

Nikolaos Ioanou, Alan M. Sedon, Angus Dalgleish, David Mackintosh, Flavio Solca, Helmout Modjtahedi

INTERNATIONAL JOURNAL OF ONCOLOGY (2016)

Article Nutrition & Dietetics

Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression

Andrius Jaksevicius, Mark Carew, Calli Mistry, Helmout Modjtahedi, Elizabeth I. Opara

NUTRIENTS (2017)

Letter Oncology

GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody-Letter

Helmout Modjtahedi, Suzanne Eccles

CLINICAL CANCER RESEARCH (2014)

Article Immunology

Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope

Mohsen Navari, Mehrak Zare, Masoud Javanmardi, Majid Asadi-Ghalehni, Helmout Modjtahedi, Mohammad Javed Rasaee

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2014)

Article Food Science & Technology

Resveratrol 3-O-D-glucuronide and resveratrol 4′-O-D-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest

Elena Polycarpou, Lisiane B. Meira, Simon Carrington, Elizabeth Tyrrell, Helmout Modjtahedi, Mark A. Carew

MOLECULAR NUTRITION & FOOD RESEARCH (2013)

Review Pharmacology & Pharmacy

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Helmout Modjtahedi, Byoung Chul Cho, Martin C. Michel, Flavio Solca

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2014)

Article Multidisciplinary Sciences

Co-Expression of HER Family Members in Patients with Dukes' C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival

Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan Michael Seddon, Helmout Modjtahedi

PLOS ONE (2014)

Article Multidisciplinary Sciences

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines

Aryan Stanley, G. Hossein Ashrafi, Alan M. Seddon, Helmout Modjtahedi

SCIENTIFIC REPORTS (2017)

Article Biotechnology & Applied Microbiology

Triple Tandem Mimotope Peptide of Epidermal Growth Factor Receptor Displaying on the Surface of M13 Phage Induces Anti-Tumor Response in Mice Tumor Model

Masoud Javanmardi, Mohammad Javad Rasaee, Helmout Modjtahedi, Majid Asadi-Ghalehni, Mohammad Ghaem Maghami

IRANIAN JOURNAL OF BIOTECHNOLOGY (2014)

Article Oncology

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

Said A. Khelwatty, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Helmout Modjtahedi

Summary: The study revealed that high levels of HER2 expression were found in CRC patients treated with cetuximab, which was associated with shorter progression free survival. The results support the emergence of HER2 as a therapeutic target in mCRC patients.

CANCERS (2021)

Review Oncology

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Gustavo A. Arias-Pinilla, Helmout Modjtahedi

Summary: Pancreatic cancer is a highly aggressive type of cancer with poor response to current treatments, leading to its high mortality rate worldwide. Monoclonal antibody technology shows promise in discovering novel therapeutic targets and developing more effective treatment options for pancreatic cancer patients, although no mAbs have been approved for this specific cancer type yet. Further research and development in this field may lead to the approval and widespread use of antibody-based agents for the treatment of pancreatic cancer in the future.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Cytokine/Chemokine Release Patterns and Transcriptomic Profiles of LPS/IFNγ-Activated Human Macrophages Differentiated with Heat-Killed Mycobacterium obuense, M-CSF, or GM-CSF

Samer Bazzi, Emale El-Darzi, Tina McDowell, Helmout Modjtahedi, Satvinder Mudan, Marcel Achkar, Charles Akle, Humam Kadara, Georges M. Bahr

Summary: The study analyzed the cytokine and chemokines release patterns of human macrophages exposed to different stimuli, revealing distinct differences in cytokine release patterns between macrophages in different activation states.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

No Data Available